{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:38:18Z","timestamp":1771486698553,"version":"3.50.1"},"reference-count":33,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:p> Treprostinil diolamine is the first oral prostacyclin approved for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity. Clinical studies have demonstrated modest benefit as monotherapy, whereas no difference in exercise capacity was observed with combination therapy. However, these trials were limited by subtherapeutic dosing owing to intolerable adverse effects. Prostacyclin-related adverse effects, such as nausea, diarrhea, headache, flushing, and jaw pain, are prevalent. More recent pharmacokinetic and clinical studies illustrate the dose\u2013response relationship and the importance of achieving clinically effective doses. Therefore, efforts to improve tolerability are paramount. Oral treprostinil is recommended to be administered three times daily in order to facilitate more rapid titration, higher doses achieved, and improved tolerability. Oral treprostinil has also been studied in carefully selected, stable patients that transitioned from parenteral or inhaled therapy with close monitoring for late deterioration. Ongoing clinical trials will determine the long-term effects of higher doses of oral treprostinil on clinical outcomes. This review describes the clinical evidence and practical experience with the use of oral treprostinil for PAH. <\/jats:p>","DOI":"10.1177\/1753466618766490","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T06:41:29Z","timestamp":1522737689000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7193-3751","authenticated-orcid":false,"given":"James C.","family":"Coons","sequence":"first","affiliation":[{"name":"Associate Professor, University of Pittsburgh School of Pharmacy, Salk Hall, Room 727, 3501 Terrace Street, Pittsburgh, PA 15261, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Miller","sequence":"additional","affiliation":[{"name":"Clinical Pharmacist, Cardiology, UPMC Presbyterian University Hospital, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,4,2]]},"reference":[{"key":"bibr1-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.911818"},{"key":"bibr2-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000675"},{"key":"bibr3-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.124388"},{"key":"bibr4-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2212"},{"key":"bibr5-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2875"},{"key":"bibr6-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.6.9804054"},{"key":"bibr7-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199207093270202"},{"key":"bibr8-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.03.012"},{"key":"bibr9-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0011OC"},{"key":"bibr10-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.6.2106079"},{"key":"bibr11-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.3.683"},{"key":"bibr12-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340504"},{"key":"bibr13-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.8.1415"},{"key":"bibr14-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1177\/1753465812455368"},{"key":"bibr15-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31828685da"},{"key":"bibr16-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12085"},{"key":"bibr17-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000039"},{"key":"bibr18-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1378\/chest.1963063"},{"key":"bibr19-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2016.06.019"},{"key":"bibr20-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201602-0274LE"},{"key":"bibr21-1753466618766490","doi-asserted-by":"crossref","first-page":"A3270","DOI":"10.1164\/rccm.201302-0318ED","volume":"187","author":"White RJ","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"bibr22-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1086\/682224"},{"key":"bibr23-1753466618766490","first-page":"A2277","volume":"195","author":"Balasubramanian VP","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"bibr24-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1086\/685111"},{"key":"bibr25-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1177\/2045893217744512"},{"key":"bibr26-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1177\/0897190017703507"},{"key":"bibr27-1753466618766490","first-page":"498981","volume":"2015","author":"Gleason JB","year":"2015","journal-title":"Case Rep Pulmonol"},{"key":"bibr28-1753466618766490","first-page":"A2280","volume":"195","author":"D\u2019Albini L","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"bibr29-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.031"},{"key":"bibr30-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-0793"},{"key":"bibr31-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"bibr32-1753466618766490","doi-asserted-by":"publisher","DOI":"10.1086\/690109"},{"key":"bibr33-1753466618766490","unstructured":"United Therapeutics. Trial of the early combination of oral treprostinil with background oral monotherapy in subjects with pulmonary arterial hypertension (FREEDOM-Ev), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01560624 (2012, accessed 8 November 2017)."}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753466618766490","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1753466618766490","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753466618766490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T02:28:07Z","timestamp":1741055287000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753466618766490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":33,"alternative-id":["10.1177\/1753466618766490"],"URL":"https:\/\/doi.org\/10.1177\/1753466618766490","relation":{},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,1]]},"article-number":"1753466618766490"}}